Bioventus Inc. (BVS) stock

BVSNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 26, 2026Last filing: 10-Q on Nov 2, 2026Score 14/3033% below fair value

$10.66−0.20 (-1.84%)

Close on Nov 13, 2026Market cap $896.42MP/E 13.3Yield –

Bioventus pe ratio

The price-to-earnings ratio is the share price divided by diluted earnings per share over the trailing twelve months.

Bioventus's pe ratio was 13.7× on Nov 11, 2026, against 69.0× a year earlier.

Period	Period end	Value	Change (pts)
2026	Nov 11, 2026	13.7×	−53.9
2025	Dec 31, 2025	67.6×	+39.4
2022	Apr 29, 2022	28.2×	–

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is BVS.

Revenue growth3.9% · median 13.8%

Gross margin68.7% · median 70.9%

Operating margin9.7% · median -2.1%

Net margin9.8% · median -3.7%

Advertisement
300 × 250

See a number that looks wrong?